Duration of degluttion apnea
duration of deglutition apnea physiology seconds
"Respiratory apnea associated with swallowing shows considerable variation across individuals, and in one study it ranged from 0.61 to 3.83 seconds."
| Feature | Detail |
|---|---|
| Duration range | 0.61 - 3.83 seconds |
| Variation | Considerable inter-individual variation |
| Effect of bolus volume | Increases in some individuals, decreases in others |
| Spontaneous swallows | Tend to have a shorter apneic period |
| Timing in respiratory cycle | Most swallows occur during expiration or late inspiration |
| Post-swallow effect | Swallowing resets the respiratory rhythm (no compensatory modification afterward) |
Physiology of high atm pressure
physiology high atmospheric pressure diving hyperbaric effects body
| Law | Statement | Relevance |
|---|---|---|
| Boyle's Law | P₁V₁ = P₂V₂ (at constant temp) | Gas-containing spaces compress on descent, expand on ascent |
| Dalton's Law | Total P = sum of partial pressures | At depth, partial pressure of each gas rises proportionally |
| Henry's Law | Gas dissolved ∝ partial pressure | More gas dissolves into blood/tissues at high pressure |
| Type | Threshold | Mechanism | Features |
|---|---|---|---|
| Pulmonary (Lorrain Smith) | >0.5 atm PO₂, prolonged exposure | Free radical damage to airway epithelium | Bronchiolar inflammation, pulmonary edema, atelectasis, fibrin formation, lung consolidation |
| CNS (Paul Bert) | ~1500 mm Hg PO₂ (~10 atm room air for >30-45 min) | Free radical oxidation of polyunsaturated fatty acids in cell membranes + energy metabolism enzymes | Muscle twitching, nausea, disorientation, irritability → seizures and coma |
| Type | Features | Mechanism |
|---|---|---|
| Type I ("mild") | Deep, unrelieved joint pain (knees, shoulders); skin mottling | Bubbles in ligaments, fascia, tendon stretch receptors, long bone intramedullary spaces |
| Type II ("serious") | Neurologic - truncal constriction, ascending paralysis, transverse myelitis; vestibular (vertigo, tinnitus, hearing loss); pulmonary (cough, dyspnea, hemoptysis) | Venous bubble occlusion in spinal cord venous plexus; autochthonous in-situ spinal cord bubbles |
| Condition | Threshold / Onset |
|---|---|
| Nitrogen narcosis | ~4-5 atm (30-40 m depth), breathing air |
| CNS oxygen toxicity | ~10 atm room air (or 1.5-2 atm pure O₂) after 30-45 min |
| Pulmonary oxygen toxicity | >0.5 atm PO₂ over many hours |
| Decompression sickness | Rapid ascent from any significant depth/duration dive |
Functionnof type 1 pneumocutes
type 1 pneumocyte function alveolar cell physiology


| Feature | Type I Pneumocyte | Type II Pneumocyte |
|---|---|---|
| Shape | Flat/squamous (extremely thin) | Cuboidal |
| % of alveolar cells (by number) | ~40% | ~60% |
| % of surface covered | ~95% | ~5% |
| Function | Gas exchange, barrier | Surfactant production, stem cell |
| Lamellar bodies | Absent | Present (surfactant storage) |
| Cell division | Cannot divide | Can divide; regenerates Type I after injury |
| Tight junctions | Yes (with other alveolar cells) | Yes |
What happens to vp ratio on moving from apex to lungs
V/Q ratio apex to base of lung changes physiology values

| Region | V̇A (L/min) | Q̇ (L/min) | V/Q | PO₂ (mmHg) | PCO₂ (mmHg) |
|---|---|---|---|---|---|
| Apex | 0.24 | 0.07 | 3.3 | 132 | 28 |
| ↓ | 0.33 | 0.19 | 1.8 | 121 | 34 |
| ↓ | 0.42 | 0.33 | 1.3 | 114 | 37 |
| ↓ | 0.52 | 0.50 | 1.0 | 108 | 39 |
| ↓ | 0.59 | 0.66 | 0.90 | 102 | 40 |
| ↓ | 0.67 | 0.83 | 0.80 | 98 | 41 |
| ↓ | 0.72 | 0.98 | 0.73 | 95 | 41 |
| ↓ | 0.78 | 1.15 | 0.68 | 92 | 42 |
| Base | 0.82 | 1.29 | 0.63 | 89 | 42 |
| Total | 5.09 | 6.00 | ~0.85 | - | - |

| Zone | Location | Pressure Relationship | Blood Flow | V/Q Effect |
|---|---|---|---|---|
| Zone 1 | Apex | PA > Pa > Pv | None (alveolar dead space) | V/Q = ∞ |
| Zone 2 | Middle upper | Pa > PA > Pv | Depends on Pa - PA (waterfall effect) | V/Q intermediate-high |
| Zone 3 | Middle-lower | Pa > Pv > PA | Full, independent of PA | V/Q intermediate-low |
| Zone 4 | Dependent base | Pa > PIS > Pv > PA | Reduced (interstitial compression) | V/Q slightly rises again |
| Region | V/Q | PO₂ | PCO₂ | Functional implication |
|---|---|---|---|---|
| Apex | High (3.3) | High (132 mmHg) | Low (28 mmHg) | Dead-space like; wastes ventilation; good TB site (high O₂) |
| Base | Low (0.63) | Low (89 mmHg) | High (42 mmHg) | Shunt-like; most blood flow but lower O₂ content |
"The base of the lung has most of the blood flow, but the PO₂ of the end-capillary blood is lowest there. As a result, the effluent pulmonary venous blood is loaded with moderately oxygenated blood from the base."
- Murray & Nadel's Textbook of Respiratory Medicine, p. 241
What causes V/Q inequality in ARDS or pneumonia 2,3 dpg
Are these two separate topics you want covered?
"Continued perfusion of alveoli that lack ventilation because of alveolar edema results in ventilation-perfusion ratios of zero, thereby defining physiologic shunt. Furthermore, the effects of this type of shunt are exacerbated by shunt-like contributions from alveoli with very low ventilation-perfusion ratios."
- Fishman's Pulmonary Diseases and Disorders, p. 2495
| Severity | Shunt fraction | Low V/Q flow |
|---|---|---|
| Mild-moderate (PaO₂ ~74 mmHg, spontaneous breathing) | 7.5 ± 1.8% | 4.2 ± 1.0% |
| Severe (mechanically ventilated, FiO₂ 0.46) | 21.9 ± 4.5% | 10.9 ± 4.6% |
| Disease | Primary V/Q Defect | O₂ Response | Mechanism |
|---|---|---|---|
| ARDS | Large true shunt | Poor | Diffuse flooding + atelectasis |
| Pneumonia | Shunt + low V/Q | Partial | Lobar/segmental consolidation |
| Pulmonary embolism | Dead space (high V/Q) | Good (for V/Q mismatch) | No perfusion to ventilated regions |
| Emphysema/asthma | Low V/Q (not shunt) | Good | Airway obstruction/airflow limitation |

| Condition | Stimulus | Effect |
|---|---|---|
| Hypoxia (any cause) | Low RBC PO₂ stimulates glycolysis | ↑ 2,3-DPG → right shift → more O₂ delivery to tissues |
| Chronic anemia | Tissue hypoxia | ↑ 2,3-DPG → compensatory O₂ unloading |
| High altitude | Hypoxemia + respiratory alkalosis | ↑ 2,3-DPG (counteracts alkalosis-induced left shift) |
| Alkalosis | Directly stimulates glycolysis | ↑ 2,3-DPG |
"Chronic hypoxia, anemia, and acclimation to high altitude are all associated with an increase in 2,3-DPG levels and thus lower the O₂ affinity of Hb."
- Medical Physiology, p. 958
| Condition | Effect |
|---|---|
| Stored blood (bank blood) | 2,3-DPG falls within hours of storage → left shift → poor O₂ delivery on transfusion (restored within 24h post-transfusion) |
| Acidosis | Inhibits glycolysis → ↓ 2,3-DPG (partially counteracts direct right shift of acidosis on Hb) |
| Fetal hemoglobin (HbF) | γ-chains bind 2,3-DPG less avidly than β-chains → effectively lower 2,3-DPG effect → left shift → HbF extracts O₂ from maternal HbA across the placenta |
"Reducing the [O₂] affinity is a two-edged sword. At the relatively high PO₂ in alveoli, where the Hb-O₂ dissociation curve is fairly flat, this decrease in O₂ affinity reduces O₂ uptake - but only slightly. At the low PO₂ in systemic tissues, where the Hb-O₂ dissociation curve is steep, this decrease in O₂ affinity markedly increases the O₂ release. The net effect is enhanced O₂ unloading to metabolizing tissues."
- Medical Physiology, p. 958
Right and left shift in respiration.

| Cause | Mechanism | Where It Occurs |
|---|---|---|
| ↑ PCO₂ | CO₂ binds Hb at non-O₂ sites, allosterically reduces O₂ affinity (Bohr effect) | Tissues (CO₂ produced by metabolism) |
| ↓ pH (acidosis) | H⁺ binds histidine residues on Hb, stabilizes deoxy (T) state (Bohr effect) | Tissues (H⁺ generated from CO₂ + lactic acid) |
| ↑ Temperature | Heat destabilizes Hb-O₂ bond | Exercising muscle, fever |
| ↑ 2,3-DPG | Binds β-chains of deoxyHb, stabilizes T-state, reduces O₂ affinity | Hypoxia, anemia, high altitude |
| Cause | Mechanism | Clinical Context |
|---|---|---|
| ↓ PCO₂ | Opposite of Bohr effect | Hyperventilation, alkalosis, pulmonary capillaries |
| ↑ pH (alkalosis) | Fewer H⁺ to stabilize T-state | Respiratory alkalosis |
| ↓ Temperature | Stabilizes Hb-O₂ bond | Hypothermia, stored blood |
| ↓ 2,3-DPG | Less stabilization of T-state | Stored bank blood (depleted within hours), hypothyroidism |
| Fetal Haemoglobin (HbF) | γ-chains bind 2,3-DPG less avidly than β-chains → effectively acts as low-2,3-DPG state → left shift | Fetus (necessary to extract O₂ from maternal HbA across placenta) |
| Methaemoglobin | Fe³⁺ cannot bind O₂; remaining Fe²⁺ sites have increased affinity | Nitrite/dapsone toxicity |
"Both hydrogen ions and carbon dioxide bind at sites on the hemoglobin molecule that differ from the oxygen-binding sites. There are many more sites that bind hydrogen ions than bind CO₂ molecules. As the tertiary and quaternary configurations of the hemoglobin molecule change with release of oxygen, 16 of these hydrogen-binding sites change their physiologic buffering capacities."
- Fishman's Pulmonary Diseases and Disorders, p. 2374

| Factor | Direction of Shift | P₅₀ | Hb-O₂ Affinity | O₂ Released to Tissues |
|---|---|---|---|---|
| ↑ PCO₂ | Right | ↑ | ↓ | ↑ |
| ↓ pH / acidosis | Right | ↑ | ↓ | ↑ |
| ↑ Temperature | Right | ↑ | ↓ | ↑ |
| ↑ 2,3-DPG | Right | ↑ | ↓ | ↑ |
| ↓ PCO₂ | Left | ↓ | ↑ | ↓ |
| ↑ pH / alkalosis | Left | ↓ | ↑ | ↓ |
| ↓ Temperature | Left | ↓ | ↑ | ↓ |
| ↓ 2,3-DPG | Left | ↓ | ↑ | ↓ |
| HbF | Left | ↓ | ↑ | ↓ (fetal adaptation) |
| CO poisoning | Left + ↓ capacity | ↓ | ↑ (catastrophic) | ↓↓ |
Right and left shift. In lungs.
| Parameter | Change | Effect on Curve |
|---|---|---|
| PCO₂ | Falls (40 → ~40 mmHg, exhaled) | Left shift (↑ Hb-O₂ affinity) |
| pH | Rises (as H⁺ is released from HbH → Hb + H⁺ → combines with HCO₃⁻ → CO₂ exhaled) | Left shift (alkalosis → ↑ affinity) |
| Temperature | Slightly lower than exercising tissues | Mild left shift |
"All of the reactions previously described occur in reverse in the lungs. H⁺ is released from its buffering sites on deoxyhemoglobin, HCO₃⁻ enters the red blood cells in exchange for Cl⁻, H⁺ and HCO₃⁻ combine to form H₂CO₃, and H₂CO₃ dissociates into CO₂ and H₂O. The regenerated CO₂ and H₂O are expired by the lungs."
- Costanzo Physiology, 7th Ed., p. 231
| Location | PCO₂ | pH | Curve Shift | Purpose |
|---|---|---|---|---|
| Tissues | ↑ (CO₂ produced) | ↓ (acidosis) | RIGHT | O₂ unloading |
| Lungs | ↓ (CO₂ exhaled) | ↑ (alkalosis) | LEFT | O₂ loading |
"Binding of O₂ with hemoglobin in the lungs causes hemoglobin to become a stronger acid. This displaces CO₂ from the blood. The Haldane effect is quantitatively far more important in promoting CO₂ transport than the Bohr effect is in promoting O₂ transport."
- Guyton & Hall Textbook of Medical Physiology
"The right shift is advantageous in the tissues because it is associated with increased P₅₀, decreased affinity, and increased unloading of O₂. However, the right shift is disadvantageous in the lungs because it becomes more difficult to load the pulmonary capillary blood with O₂."
- Costanzo Physiology, 7th Ed., p. 232
| Context | Shift | P₅₀ | Net Effect |
|---|---|---|---|
| Normal lungs (reverse Bohr) | LEFT | ↓ | Haemoglobin loads O₂ efficiently from alveolar air |
| Exercising tissues (Bohr effect) | RIGHT | ↑ | Haemoglobin releases O₂ to tissues |
| High altitude / ↑ 2,3-DPG | Right (even in lungs) | ↑ | Impairs O₂ loading slightly - disadvantageous at the lung |
| Hyperventilation / alkalosis | LEFT (in lungs) | ↓ | Enhanced O₂ loading - but may cause cerebral vasoconstriction |
Herriring breurer reflex and j receptors
"When the lungs become overinflated, the stretch receptors activate a feedback response that 'switches off' the inspiratory ramp and stops further inspiration."
- Guyton & Hall Textbook of Medical Physiology
| Population | Threshold | Role |
|---|---|---|
| Human infants | Normal tidal volumes | Important in controlling tidal volume during eupnea |
| Human adults | Only when tidal volume > ~1.5 L (3× normal) | Mainly a protective mechanism against dangerous over-inflation, NOT a major control of normal quiet breathing |
"In humans, the Hering-Breuer reflex probably is not activated until the tidal volume increases to more than three times normal (~1.5 L/breath). Therefore, this reflex appears to be mainly a protective mechanism for preventing excess lung inflation rather than an important factor in normal control of ventilation."
- Guyton & Hall, p. 533
| Feature | Detail |
|---|---|
| Receptor | Slowly adapting pulmonary stretch receptors (SAPSRs) |
| Location | Smooth muscle of bronchi/bronchioles |
| Fibre | Myelinated, vagus nerve |
| Stimulus | Lung over-inflation/stretch |
| Reflex arc | Vagus → DRG medulla → stops inspiratory ramp |
| Effect | Terminates inspiration; ↑ expiratory duration; ↑ RR |
| Clinical importance (adults) | Protective, not routine breathing regulation |
| Abolished by | Vagotomy |
"Alveolar C-fiber receptors become active very soon (1-2 seconds) after injection of certain chemicals into the blood of the right atrium of the heart, which suggests that the receptors may be very near pulmonary capillaries. Hence the name juxtacapillary or J receptors."
- Medical Physiology (Boron & Boulpaep), p. 1071
| Stimulus Type | Examples |
|---|---|
| Chemical - inflammatory mediators | Histamine, serotonin, bradykinin, prostaglandins |
| Chemical - exogenous | Capsaicin (IV), phenyl diguanide |
| Mechanical | Lung congestion (pulmonary oedema), vascular engorgement |
| Hyperinflation | Extreme lung distension |
| Pulmonary embolism | Via chemical mediator release |
"The reflex response that is produced is apnea followed by rapid breathing, bradycardia, and hypotension (pulmonary chemoreflex)."
- Ganong's Review of Medical Physiology
| Condition | Role of J Receptors |
|---|---|
| Pulmonary oedema | Activated by interstitial fluid congestion → rapid shallow breathing + dyspnoea sensation |
| Pulmonary embolism | Activated by released mediators (serotonin, bradykinin) → reflex apnea/tachypnea |
| Pneumonia/inflammation | Activated by histamine, prostaglandins |
| Exercise | May contribute to dyspnoea sensation |
| Heart failure | Pulmonary capillary congestion activates J receptors → orthopnoea, dyspnoea |
| Normal physiology | Role uncertain; likely a pathological defense mechanism |
| Feature | Slowly Adapting PSRs (Hering-Breuer) | Rapidly Adapting (Irritant) Receptors | J Receptors / C-fibres |
|---|---|---|---|
| Fibre type | Myelinated | Myelinated | Unmyelinated (C fibres) |
| Location | Airway smooth muscle (bronchi/bronchioles) | Airway epithelium (trachea to bronchioles) | Alveolar wall, near capillaries |
| Adapts? | Slowly (sustained) | Rapidly (fast) | Slow |
| Stimulus | Inflation/stretch | Chemicals, irritants, sudden inflation | Congestion, inflammation, chemicals |
| Reflex | Hering-Breuer (stop inspiration) | Cough, bronchoconstriction, mucus secretion | Apnea → rapid breathing, bradycardia, hypotension |
| Blocked by | Cooling (~8-10°C) | Cooling | NOT blocked by cooling |
Bezold jarisch reflex
Bezold-Jarisch reflex mechanism clinical significance cardiology
Bradycardia + Hypotension + Apnea (followed by rapid shallow breathing)
| Type | Examples |
|---|---|
| Veratrum alkaloids (original stimulus) | Veratridine, veratrine |
| Serotonin (5-HT₃) | Released during ischaemia/reperfusion |
| Capsaicin | Substance P pathway |
| Phenylbiguanide / phenylguanide | Experimental |
| Histamine | Allergic/inflammatory states |
| Nicotine | |
| Snake and insect venoms | |
| Contrast media | During coronary angiography |
| Thrombolytic agents | During reperfusion |
| Oxygen free radicals | Myocardial ischaemia/reperfusion |
| Ventricular under-filling | Upright posture, hypovolaemia |
| Response | Mechanism |
|---|---|
| Bradycardia | Increased parasympathetic tone → slowing of SA node |
| Hypotension | Vasodilation (loss of sympathetic tone) + decreased cardiac output |
| Apnea → then rapid shallow breathing | C-fibre activation in cardiopulmonary region |
| (Also) Coronary artery dilation | Possibly cardioprotective |
"The Bezold-Jarisch reflex responds to noxious ventricular stimuli sensed by chemoreceptors and mechanoreceptors within the left ventricular wall by inducing the triad of hypotension, bradycardia, and coronary artery dilatation."
- Miller's Anesthesia, 10th Ed.
"Pressure receptors in the wall of the left ventricle respond by sending signals that trigger paradoxical bradycardia and decreased contractility, resulting in sudden marked hypotension."
- Ganong's Review of Medical Physiology
Emotional stress / standing / blood loss
↓
Reduced ventricular filling
↓
Vigorous contraction of under-filled LV
↓
Activation of LV inferoposterior mechanoreceptors
↓
C-fibre vagal afferents → NTS → medulla
↓
↑ Parasympathetic + ↓ Sympathetic output
↓
Bradycardia + Vasodilation + ↓ Cardiac output
↓
↓ Mean arterial pressure → Cerebral hypoperfusion
↓
Syncope (loss of consciousness in ~10 seconds)
| Feature | Detail |
|---|---|
| Receptor | LV chemoreceptors/mechanoreceptors (inferoposterior wall) |
| Afferent | Unmyelinated C fibres → vagus nerve → NTS |
| Efferent | ↑ Parasympathetic + ↓ Sympathetic |
| Triad | Bradycardia + Hypotension + Apnea → tachypnea |
| Also | Coronary vasodilation |
| Key clinical scenario | Vasovagal syncope, inferior MI, spinal anaesthesia, coronary angiography |
| Protective role | Coronary dilation in inferoposterior ischaemia |
Homometeric and heterometeric regulation
"When cardiac output is regulated by changes in cardiac muscle fiber length, this is referred to as heterometric regulation."
- Ganong's Review of Medical Physiology
"There is also a substantial increase in myofilament Ca²⁺ sensitivity with an increase in sarcomere length... the myocyte is at constant volume, so as the cell shortens it must thicken, and conversely, when stretched, the cell becomes thinner and filament spacing becomes narrower."
- Braunwald's Heart Disease
| Situation | ↑ Preload → ↑ EDV → |
|---|---|
| Increased venous return (exercise, fluid loading) | ↑ Stroke volume (self-compensating) |
| Sudden volume load | ↑ Force to eject the extra volume |
| Aortic regurgitation | Dilated LV → ↑ EDV → ↑ contractile force |
| Right heart receiving more blood from leg veins (standing → lying) | ↑ RV output automatically |
"Regulation due to changes in contractility independent of length is sometimes called homometric regulation."
- Ganong's Review of Medical Physiology
"Conditions in which contraction is strengthened independent of sarcomere length (e.g., typically by increased Ca²⁺ transient amplitude) are referred to as positive inotropic states or enhanced contractility."
- Braunwald's Heart Disease
"An increased HR progressively enhances the force of ventricular muscle contraction... the Bowditch staircase phenomenon (treppe = German for 'steps')"
- Braunwald's Heart Disease
"When the aortic pressure is elevated abruptly, ejection is limited, tending to increase EDV, which acutely increases force by the Frank-Starling effect. However, in a slower adaptation (seconds to minutes), the inotropic state of the heart increases (larger Ca²⁺ transients). This slow force response is referred to as the Anrep effect."
- Braunwald's Heart Disease
| Drug | Mechanism | Effect |
|---|---|---|
| Digoxin | Inhibits Na⁺/K⁺-ATPase → ↑ intracellular Na⁺ → ↑ Ca²⁺ via NCX | ↑ Contractility |
| Dobutamine | β₁ agonist | ↑ cAMP → ↑ Ca²⁺ |
| Milrinone | PDE inhibitor → ↑ cAMP | ↑ Ca²⁺ |
| β-blockers | ↓ sympathetic tone | ↓ Contractility (negative inotropy) |
| Feature | Heterometric Regulation | Homometric Regulation |
|---|---|---|
| Also called | Frank-Starling mechanism, preload regulation | Inotropic regulation, contractility regulation |
| Depends on | Change in fibre/sarcomere length (preload/EDV) | Change in Ca²⁺ transient - independent of length |
| Frank-Starling curve | Movement along the curve | Shift of the curve (up = positive, down = negative inotropy) |
| Key variable | End-diastolic volume | Intracellular [Ca²⁺] per beat |
| Molecular basis | ↑ Sarcomere length → ↑ myofilament Ca²⁺ sensitivity | ↑ Ca²⁺ release from SR |
| Classic examples | Starling's law, increased venous return | Sympathetic stimulation, Bowditch/treppe, Anrep effect |
| Clinical context | Volume loading, heart failure compensation (initial) | Catecholamines, inotropic drugs, heart rate changes |
| Limits | Cannot compensate indefinitely (descending limb) | Limited by SR Ca²⁺ stores and receptor downregulation |
| Condition | Dominant Regulatory Mechanism |
|---|---|
| Normal resting heart | Both; heterometric maintains baseline output |
| Exercise | Both: ↑ venous return (heterometric) + sympathetic activation (homometric) |
| Heart failure | Initially compensated by heterometric (dilated heart) → eventually fails; drugs target homometric |
| Pulmonary hypertension (RV) | Homeometric (Anrep): RV hypertrophies and increases contractility without dilation |
| Inotropic drug therapy | Pure homometric - improve contractility without increasing preload |
Heart blocks
| Cause | Examples |
|---|---|
| Ischaemia | Coronary artery disease; inferior MI (RCA) → AV nodal block; anterior MI → infranodal block |
| Inflammation | Rheumatic fever, myocarditis, endocarditis, Lyme disease, Chagas disease |
| Degeneration | Lenègre disease (fibrosis of conduction system), Lev disease (calcification), ageing |
| Drugs | Digoxin, β-blockers, calcium channel blockers, amiodarone |
| Compression | Scar tissue, calcified areas |
| Vagal excess | Carotid sinus syndrome, vasovagal reactions |
| Congenital | Associated with maternal SLE (anti-Ro antibodies) |
| Infiltrative | Sarcoidosis, amyloidosis, haemochromatosis |



| Site of escape pacemaker | Rate | QRS |
|---|---|---|
| AV node / His bundle (above bifurcation) | 45-60 bpm | Narrow (QRS ≤0.12 sec) |
| Bundle branches / Purkinje (infranodal) | 30-45 bpm | Wide (QRS >0.12 sec) |
| Ventricular myocardium | <30 bpm | Very wide, bizarre |
| Feature | 1st Degree | 2nd Degree Mobitz I | 2nd Degree Mobitz II | 3rd Degree |
|---|---|---|---|---|
| PR interval | Prolonged (fixed) | Progressively ↑ | Fixed (normal) | No relationship |
| Dropped beats | None | Yes (periodic) | Yes (sudden) | All P waves blocked |
| QRS | Narrow | Narrow | Often wide | Narrow or wide (escape) |
| Site | AV node | AV node | Infranodal | Any level |
| Ventricular rate | Normal | Slightly reduced | Reduced | Very slow (escape) |
| Risk of progression | Low | Low | High | - |
| Atropine response | - | Helps | Worsens | Minimal effect |
| Treatment | None | Usually none | Pacemaker | Pacemaker |
| RBBB | LBBB | |
|---|---|---|
| QRS duration | >0.12 sec | >0.12 sec |
| V1 | rSR' ("M" pattern) | QS or rS |
| V6 | Wide S wave | Broad R, no q |
| Significance | Often benign; RV strain | Usually significant LV disease |
| Block Type | Management |
|---|---|
| 1st degree | Treat cause; avoid offending drugs; no pacing needed |
| Mobitz I | Treat cause; atropine if symptomatic; usually no pacemaker |
| Mobitz II | Pacemaker (high risk of sudden complete block) |
| Complete (3rd degree) | Emergency temporary pacing → permanent pacemaker |
| Acute inferior MI + AV block | Often transient; atropine; temporary pacing if needed |
| Acute anterior MI + AV block | Serious (large infarct); emergency pacing |
Acregaly and gigantism characteristic features
| Gigantism | Acromegaly | |
|---|---|---|
| Age of onset | Before epiphyseal closure (childhood/adolescence) | After epiphyseal closure (adults) |
| Epiphyses | Open → bones grow in length | Fused → bones grow in width/thickness |
| Result | Proportional tall stature (up to 8 feet) | Soft tissue + acral + membranous bone changes |
| GH mediator | IGF-1 (somatomedin C) | Same |
"All body tissues grow rapidly, including the bones. If the condition occurs before adolescence, before the epiphyses of the long bones have fused, height increases so that the person may develop gigantism and become up to 8 feet tall." - Guyton & Hall
| Feature | Details |
|---|---|
| Stature | Proportional tall stature (>8 feet possible) |
| Growth rate | Abnormally rapid from childhood |
| Body proportions | Proportional (unlike Marfan's which has disproportionate limbs) |
| Hyperglycaemia | Present; beta cells overworked |
| Diabetes mellitus | Develops in ~10% of cases |
| Panhypopituitarism | Eventually - as expanding tumor destroys normal pituitary |
| Prognosis | Death in early adulthood if untreated; panhypopituitarism is the usual cause |
| Feature | Mechanism |
|---|---|
| Frontal bossing | Enlarged supraorbital ridges (membranous bone growth) |
| Prognathism | Mandibular overgrowth - lower jaw protrudes forward (sometimes up to ½ inch) |
| Malocclusion / splayed teeth | Mandibular enlargement; widened lower incisor spacing |
| Macroglossia | Enlarged tongue |
| Large fleshy nose | May double in size |
| Coarse facial features | Thickened, reddened, wrinkled forehead; exaggerated nasolabial grooves |
| Cutis verticis gyrata | Skin folds on scalp (~30% of patients) |
| Deep/hollow-sounding voice | Enlarged vocal cords and pharyngeal soft tissue |
| Feature | Notes |
|---|---|
| Hyperhidrosis | Very common; sweating at rest; persists after treatment in most |
| Oily skin | GH/IGF-1-driven sebaceous gland hypertrophy |
| Skin tags (acrochordon) | Multiple; strongly associated with colonic polyps |
| Acanthosis nigricans | Insulin resistance marker |
| Hypertrichosis | Excess hair growth |
| Hyperpigmentation | Present in many patients |
| Diffuse skin thickening | Collagen deposition in dermis; measurable on heel pad X-ray |
| Feature | Notes |
|---|---|
| Arthropathy | Large and small joints; cartilage overgrowth, then destruction → OA |
| Kyphosis | Vertebral changes → hunched back |
| Carpal tunnel syndrome | Nerve entrapment by soft tissue/bony overgrowth (25% of patients) |
| Proximal muscle weakness | Myopathy |
| Paresthesias | Peripheral neuropathy |
| Complication | Frequency/Notes |
|---|---|
| Glucose intolerance | Most patients; GH is counter-regulatory (anti-insulin) |
| Diabetes mellitus | ~25% |
| Hyperlipidaemia | Raised triglycerides |
| Hypercalciuria / kidney stones | GH stimulates renal 1α-hydroxylase → ↑ calcitriol → ↑ Ca²⁺ absorption |
| Goitre/thyroid enlargement | ~50% |
| Hyperprolactinaemia | ~25% of tumours co-secrete prolactin; galactorrhea in women |
| Hypogonadism | Tumour mass effect on gonadotrophs; menstrual irregularity, reduced libido |
| Feature | Gigantism | Acromegaly |
|---|---|---|
| Timing | Pre-pubertal | Post-pubertal |
| Height | ↑↑↑ proportional | Normal or slightly ↑ |
| Hands/feet | Proportionally large | Spade-shaped, acral enlargement |
| Facial changes | Less obvious | Prominent (prognathism, frontal bossing, coarse features) |
| Bone growth | Longitudinal | Periosteal/membranous thickening |
| Joints | Variable | Arthropathy, carpal tunnel |
| Metabolic | Hyperglycaemia, DM in 10% | DM in 25%, hypertension, dyslipidaemia |
| Cause of death | Panhypopituitarism | Cardiovascular disease |
| Prognosis | Death in early adulthood if untreated | Survival ↓ ~10 years if uncontrolled |
| Modality | Details |
|---|---|
| Transsphenoidal surgery | First-line for most; microadenomas: cure in 80-90%; macroadenomas: <30% cure but GH significantly reduced |
| Somatostatin analogues | Octreotide LAR / Lanreotide - monthly IM depot injections; suppress GH in ~70%; shrink tumour; used pre-op, post-op, or if surgery not feasible |
| GH receptor antagonist | Pegvisomant - blocks GH receptor peripherally; normalises IGF-1 in >90%; used for resistant cases |
| Dopamine agonists | Bromocriptine / Cabergoline - adjunctive; suppress GH in some; especially useful when co-secreting prolactin |
| Radiotherapy | Last resort; GH falls slowly (may take 5-10 years); risk of hypopituitarism and secondary tumours; stereotactic radiosurgery (SRS/Gamma Knife) preferred |